港股異動 | 新鋭醫藥(6108.HK)繼續飆漲125% 4月以來已累漲超1500%
格隆匯4月20日丨昨日暴漲152.78%的新鋭醫藥(6108.HK)今日繼續飆升,盤中一度大漲125%至2.05港元,4月以來已累漲超1500%。據悉,新鋭醫藥是一家醫藥分銷商,2013年登陸港交所;2017年時,香港證監會認為該公司的兩項收購資料可能包含重大失實、不完整或具誤導性資料,勒令其於2017年10月6日起停牌。今年3月22日該股復牌,復牌後股價先跌後漲走出“u”型走勢。此外據悉,新鋭醫藥曾公佈截至2021年12月31日止年度業績,期內錄得收益約3.35億港元,同比增約151.8%;公司擁有人應占淨虧損約為280萬港元,較2020年虧損同比收窄約96%。公司稱,二代頭孢產品銷量增長是收入大增的主因,同時,減值虧損顯著降低也成為盈利減虧的重要因素。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.